Liquidia (NASDAQ:LQDA) Stock Rating Cut to Hold at Wall Street Zen

Wall Street Zen lowered shares of Liquidia (NASDAQ:LQDA) from a buy rating to a hold rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Other research analysts also recently issued reports about the stock. Lifesci Capital downgraded shares of Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 price target on the stock. in a research report on Wednesday, August 12th. Citigroup restated a “neutral” rating on shares of Liquidia in a research note on Thursday. Stephens set a $130.00 target price on Liquidia in a report on Friday, July 24th. Jefferies Financial Group upgraded Liquidia to a “strong-buy” rating in a research report on Thursday. Finally, Royal Bank Of Canada set a $130.00 target price on Liquidia in a research report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $83.69.

Liquidia Price Performance

NASDAQ LQDA opened at $28.64 on Friday. Liquidia has a 52 week low of $21.91 and a 52 week high of $93.61. The firm has a market capitalization of $2.56 billion, a P/E ratio of 20.91 and a beta of 0.61. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. The company has a 50-day moving average price of $71.62 and a 200-day moving average price of $62.02.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The business had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The business’s quarterly revenue was up 1842.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.49) EPS. Equities research analysts anticipate that Liquidia will post 2.34 earnings per share for the current year.

Insider Transactions at Liquidia

In related news, insider Rajeev Saggar sold 50,000 shares of Liquidia stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $74.06, for a total transaction of $3,703,000.00. Following the transaction, the insider owned 142,265 shares in the company, valued at approximately $10,536,145.90. The trade was a 26.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Katherine Rielly-Gauvin sold 18,393 shares of the company’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $72.23, for a total transaction of $1,328,526.39. Following the completion of the transaction, the director directly owned 44,637 shares of the company’s stock, valued at $3,224,130.51. This represents a 29.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 597,519 shares of company stock valued at $46,091,764. Company insiders own 25.60% of the company’s stock.

Institutional Investors Weigh In On Liquidia

A number of institutional investors and hedge funds have recently bought and sold shares of LQDA. Globeflex Capital L P bought a new position in shares of Liquidia in the second quarter worth about $175,000. Nykredit A S bought a new stake in Liquidia during the 2nd quarter valued at approximately $177,000. Hurley Capital LLC raised its stake in Liquidia by 140.7% during the 4th quarter. Hurley Capital LLC now owns 5,200 shares of the company’s stock valued at $179,000 after purchasing an additional 3,040 shares during the period. Apollon Wealth Management LLC bought a new stake in Liquidia during the 1st quarter valued at approximately $247,000. Finally, Archer Investment Corp purchased a new position in Liquidia in the 1st quarter worth approximately $259,000. 64.54% of the stock is owned by institutional investors.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia’s legal options are not exhausted: an appeal could potentially overturn or narrow the ruling, giving investors a possible path to recovery if Yutrepia’s market opportunity is preserved. Liquidia Stock Crashed 57% in a Day After a Delaware Court Ruling
• Positive Sentiment: Despite the litigation setback, Jefferies upgraded LQDA to “strong buy,” while HC Wainwright maintained a “buy” rating and set a $58 price target. These calls indicate that some analysts believe the selloff has overstated the long-term damage or that an appeal could succeed.
• Neutral Sentiment: HC Wainwright cut its target from $130 to $58, and Needham reduced its target from $110 to $72, although both retained “buy” ratings. The sharply lower targets reflect materially higher legal and commercialization risk even among bullish analysts.
• Negative Sentiment: BTIG downgraded Liquidia to “neutral,” and Wells Fargo added to the analyst downgrades following the patent ruling. Analysts cited uncertainty over Yutrepia’s PH-ILD indication and the possibility that UTHR’s patent victory could limit Liquidia’s addressable market. Liquidia extends losses as Wells Fargo adds to downgrades
• Negative Sentiment: The court setback triggered a severe selloff, leaving LQDA on track for its worst week on record as investors reassessed Yutrepia’s revenue potential and Liquidia’s competitive position. The stock’s unusually heavy trading volume underscores the market’s heightened uncertainty. LQDA Stock On Track For Worst Week Ever

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).